BioWorld MedTech

Feb. 8, 2016

Boston Scientific's CRM suffers in 4Q, but near-term improvement is expected

Competition from Medtronic plc hurt Boston Scientific Corp.'s cardiac rhythm management (CRM) business in the fourth quarter, analysts noted after Boston Scientific reported its earnings for the quarter. Read More

Medtronic brings home FDA approval for MRI conditional CRT-D technology

WPS proposes noncoverage for cardiovascular risk panels

Labgenomics aggressively expands into global markets

Viral or bacterial? Febridx differentiates to mitigate antibiotic overuse

MDD's Company Stock Report

Other news to note

Financings

Product briefs

MDD's Neurology Extra

Today's news in brief

BioWorld

BioWorld briefs for Jan 16, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 16, 2026.

Illustration of human body surrounded by DNA, cell and drug icons

Cell/gene therapy sector now sustainable; China competition mounting

BioWorld

There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...

Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal

BioWorld

With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...

DNA mutations or genetic disorder concept art

Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease

BioWorld Science

Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...